Hologic, Inc. (NASDAQ:HOLX) Shares Bought by California Public Employees Retirement System

California Public Employees Retirement System increased its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,422,317 shares of the medical equipment provider's stock after purchasing an additional 27,461 shares during the quarter. California Public Employees Retirement System owned approximately 0.61% of Hologic worth $101,625,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Nordea Investment Management AB raised its holdings in Hologic by 4.5% in the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider's stock worth $113,077,000 after purchasing an additional 69,494 shares during the period. Pathstone Family Office LLC raised its holdings in Hologic by 96.0% during the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider's stock valued at $643,000 after acquiring an additional 4,542 shares during the period. Ontario Teachers Pension Plan Board raised its holdings in Hologic by 186.7% during the third quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider's stock valued at $2,665,000 after acquiring an additional 25,010 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Hologic by 145.3% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider's stock valued at $56,000 after acquiring an additional 468 shares during the period. Finally, HB Wealth Management LLC raised its holdings in Hologic by 18.1% during the third quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider's stock valued at $401,000 after acquiring an additional 884 shares during the period. 94.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on HOLX shares. Raymond James raised their price target on Hologic from $85.00 to $88.00 and gave the company an "outperform" rating in a report on Friday, February 2nd. William Blair reissued an "outperform" rating on shares of Hologic in a report on Friday, February 2nd. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price target for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Evercore ISI raised their price objective on Hologic from $76.00 to $78.00 and gave the company an "in-line" rating in a research report on Thursday, April 4th. Finally, Needham & Company LLC restated a "buy" rating and set a $90.00 price objective on shares of Hologic in a research report on Wednesday, April 10th. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $87.00.

Hologic Trading Down 0.6 %

HOLX traded down $0.48 on Wednesday, hitting $76.71. The company had a trading volume of 963,154 shares, compared to its average volume of 1,787,079. The company has a market cap of $18.01 billion, a PE ratio of 36.58, a PEG ratio of 2.58 and a beta of 1.00. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $87.88. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The business's fifty day simple moving average is $75.87 and its 200 day simple moving average is $72.69.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm's revenue was down 5.7% on a year-over-year basis. During the same quarter last year, the business posted $1.07 earnings per share. Equities research analysts expect that Hologic, Inc. will post 4.01 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the business's stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Charles J. Dockendorff sold 1,465 shares of the business's stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares of the company's stock, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Karleen Marie Oberton sold 14,940 shares of the business's stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares of the company's stock, valued at approximately $7,793,700. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock worth $2,473,443 over the last 90 days. Company insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.